Comparison between maximal left ventricular wall thickness and left ventricular mass in patients with hypertrophic

Mateusz Spiewak1, Lidia Chojnowska, Lukasz A Małek

  • 1Department of Coronary Artery Disease and Structural Heart Diseases, Institute of Cardiology, Warsaw, Poland. mspiewak@ikard.pl

Kardiologia Polska
|July 22, 2010
PubMed

Insights

Maximal left ventricular wall thickness (MLVWT) does not accurately reflect left ventricular mass (LVM) in hypertrophic cardiomyopathy (HCM). Patients with similar MLVWT can have significantly different LVM, highlighting the need for comprehensive assessment in HCM.

Area of Science:

  • Cardiology
  • Medical Imaging

Background:

  • Cardiovascular magnetic resonance (CMR) provides accurate assessment of left ventricular (LV) dimensions and function.
  • Left ventricular mass (LVM) and maximal LV wall thickness (MLVWT) are prognostically significant in hypertrophic cardiomyopathy (HCM).

Purpose of the Study:

  • To compare MLVWT and LVM in patients with HCM.
  • To evaluate the relationship between MLVWT and LVM in HCM patients.

Main Methods:

  • Cardiac magnetic resonance (CMR) was used to measure MLVWT and LVM in 33 HCM patients.
  • MLVWT was determined from short-axis slices, and LVM was indexed to body surface area.
  • Exclusion criteria included prior alcohol septal ablation or surgical myectomy.

Main Results:

  • Mean LVM was 107.4 ± 30.9 g/m², higher in males than females (p=0.01).
  • Mean MLVWT was 23.4 ± 4.8 mm, with no significant difference between sexes (p=0.09).
  • No significant correlation was found between LVM and MLVWT (r=0.24, p=0.17), with substantial variability in LVM for similar MLVWT.

Conclusions:

  • MLVWT is not a reliable indicator of the degree of LV hypertrophy in HCM.
  • Significant differences in LVM exist among HCM patients with similar MLVWT.
  • A notable proportion of HCM patients exhibit normal or mildly increased LVM despite significant MLVWT.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...